medicare coverage for glp-1 drugs cuts cost of popular weight-loss eligible seniors Access to GLP-1s for Medicare
Description
Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials
Low prices are expected to lead to more accessibility and higher demand
For health-conscious individuals, supplements arent shortcuts, theyre strategic additions
Mercedez Hernandez walks through what patients should consider when weighing their options.
Liquivida offers medically supervised GLP-1 weight loss injections
